LENZ Therapeutics Statistics
Share Statistics
LENZ Therapeutics has 27.54M
shares outstanding. The number of shares has increased by 7.87%
in one year.
| Shares Outstanding | 27.54M |
| Shares Change (YoY) | 7.87% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | 71.26% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 511 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -12.34 and the forward
PE ratio is -8.26.
LENZ Therapeutics's PEG ratio is
0.15.
| PE Ratio | -12.34 |
| Forward PE | -8.26 |
| PS Ratio | 0 |
| Forward PS | 2.4 |
| PB Ratio | 3.01 |
| P/FCF Ratio | -10.26 |
| PEG Ratio | 0.15 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for LENZ Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.36,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 20.36 |
| Quick Ratio | 20.36 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-8,294,833.33 |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 76.48% in the
last 52 weeks. The beta is 0.4, so LENZ Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.4 |
| 52-Week Price Change | 76.48% |
| 50-Day Moving Average | 24.08 |
| 200-Day Moving Average | 25.95 |
| Relative Strength Index (RSI) | 62.98 |
| Average Volume (20 Days) | 224,134 |
Income Statement
| Revenue | n/a |
| Gross Profit | -58K |
| Operating Income | -58.61M |
| Net Income | -49.77M |
| EBITDA | -49.71M |
| EBIT | -49.77M |
| Earnings Per Share (EPS) | -2.34 |
Full Income StatementBalance Sheet
The company has 20.16M in cash and 1.38M in
debt, giving a net cash position of 18.78M.
| Cash & Cash Equivalents | 20.16M |
| Total Debt | 1.38M |
| Net Cash | 18.78M |
| Retained Earnings | -145.01M |
| Total Assets | 215.3M |
| Working Capital | 201.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -59.39M
and capital expenditures -468K, giving a free cash flow of -59.86M.
| Operating Cash Flow | -59.39M |
| Capital Expenditures | -468K |
| Free Cash Flow | -59.86M |
| FCF Per Share | -2.81 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
